CN118541372A - 用于治疗癌症的双环三嗪衍生物 - Google Patents

用于治疗癌症的双环三嗪衍生物 Download PDF

Info

Publication number
CN118541372A
CN118541372A CN202380016568.XA CN202380016568A CN118541372A CN 118541372 A CN118541372 A CN 118541372A CN 202380016568 A CN202380016568 A CN 202380016568A CN 118541372 A CN118541372 A CN 118541372A
Authority
CN
China
Prior art keywords
trifluoromethyl
group
triazin
methyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380016568.XA
Other languages
English (en)
Chinese (zh)
Inventor
凯·锡德
菲利普·布赫格拉伯尔
格哈德·西米斯特
帕特里克·斯泰格曼
安特耶·玛格丽特·温纳
乌尔夫·伯默
菲利普·利瑙
弗兰克·韦斯特曼
安诺·格利姆
弗里德里克·赫布斯特-诺鲁齐
塞巴斯蒂安·迪特尔
西纳·克雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of CN118541372A publication Critical patent/CN118541372A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380016568.XA 2022-01-11 2023-01-06 用于治疗癌症的双环三嗪衍生物 Pending CN118541372A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22150829 2022-01-11
EP22150829.4 2022-01-11
PCT/EP2023/050208 WO2023135057A1 (en) 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN118541372A true CN118541372A (zh) 2024-08-23

Family

ID=79927598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380016568.XA Pending CN118541372A (zh) 2022-01-11 2023-01-06 用于治疗癌症的双环三嗪衍生物

Country Status (9)

Country Link
US (1) US20250066370A1 (https=)
EP (1) EP4463458A1 (https=)
JP (1) JP2025502240A (https=)
KR (1) KR20240134962A (https=)
CN (1) CN118541372A (https=)
AU (1) AU2023207765A1 (https=)
CA (1) CA3246440A1 (https=)
IL (1) IL313835A (https=)
WO (1) WO2023135057A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021176045A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
WO2021176045A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
WO2021176049A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12

Also Published As

Publication number Publication date
KR20240134962A (ko) 2024-09-10
WO2023135057A1 (en) 2023-07-20
EP4463458A1 (en) 2024-11-20
CA3246440A1 (en) 2023-07-20
JP2025502240A (ja) 2025-01-24
AU2023207765A1 (en) 2024-07-04
US20250066370A1 (en) 2025-02-27
IL313835A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
JP7747799B2 (ja) ４，５－縮環１，２，４－トリアゾロン
EP3661517B1 (en) Dihydrooxadiazinones
EP3390387B1 (en) Heteroarylbenzimidazole compounds
CN115485030A (zh) 咪唑并三嗪通过抑制cdk12作用于癌症
US20200123147A1 (en) Thiazole compounds useful as prmt5 inhibitors
CN106414435A (zh) 氨基‑取代的异噻唑
WO2020126968A2 (en) Urea derivatives
US20230117034A1 (en) Pyrazolotriazines
US20250170136A1 (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
US20230192700A1 (en) Pyrazolopyrazines acting on cancers via inhibition of cdk12
CN118541372A (zh) 用于治疗癌症的双环三嗪衍生物
CN119894893A (zh) 用于治疗癌症的砜取代的吡啶并[3,4-d]嘧啶衍生物
WO2017207534A1 (en) Substituted heteroarylbenzimidazole compounds
HK40085534A (en) Imidazotriazines acting on cancer via inhibition of cdk12
HK1226398A1 (zh) 作为midh1抑制剂的苯并咪唑-2-胺
HK1234390A1 (en) Amino-substituted isothiazoles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination